Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1982 Dec;48(6):541–545. doi: 10.1136/hrt.48.6.541

Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension.

H Ikram, A H Maslowski, M G Nicholls, E A Espiner, F T Hull
PMCID: PMC482745  PMID: 6756445

Abstract

The treatment of primary pulmonary hypertension is unsatisfactory. Since, in animals, experimental pulmonary vasoconstriction may be mediated in part by angiotensin II, we treated five primary pulmonary hypertensive patients with captopril for four days. To ensure accuracy of haemodynamic and hormone data, the patients were studied under conditions of constant body posture, regulated dietary sodium and potassium intake, and unchanged diuretic therapy. Captopril reduced mean pulmonary arterial pressure in parallel with plasma angiotensin II levels. Right ventricular ejection fraction recordings increased considerably in three of four patients. Systemic arterial pressure fell, but there was no change in right atrial pressure, cardiac output, or heart rate. The decline in plasma (and urine) aldosterone levels presumably contributed to the positive cumulative potassium balance and the rise in plasma potassium (mean 0.7 mmol/1). These encouraging results suggest that converting enzyme inhibitors warrant a formal trial with prolonged follow up in the treatment of primary pulmonary hypertension.

Full text

PDF
541

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger H. J., Matthay R. A., Loke J., Marshall R. C., Gottschalk A., Zaret B. L. Assessment of cardiac performance with quantitative radionuclide angiocardiography: right ventricular ejection fraction with reference to findings in chronic obstructive pulmonary disease. Am J Cardiol. 1978 May 1;41(5):897–905. doi: 10.1016/0002-9149(78)90731-2. [DOI] [PubMed] [Google Scholar]
  2. Bourdillon P. D., Oakley C. M. Regression of primary pulmonary hypertension. Br Heart J. 1976 Mar;38(3):264–270. doi: 10.1136/hrt.38.3.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Charters A. D., Baker W. de C. Primary pulmonary hypertension of unusually long duration. Br Heart J. 1970 Jan;32(1):130–133. doi: 10.1136/hrt.32.1.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ellis J. H., Jr, Kirch D., Steele P. P. Right ventricular ejection fraction in severe chronic airway obstruction. Chest. 1977 Feb;71(2 Suppl):281–282. doi: 10.1378/chest.71.2_supplement.281. [DOI] [PubMed] [Google Scholar]
  5. Gupta B. D., Moodie D. S., Hodgman J. R. Primary pulmonary hypertension in adults; clinical features, catheterization findings and long-term follow up. Cleve Clin Q. 1980 Winter;47(4):275–284. doi: 10.3949/ccjm.47.4.275. [DOI] [PubMed] [Google Scholar]
  6. Horowitz J. D., Brennan J. B., Oliver L. E., Harding D., Goble A. J., Louis W. J. Effects of captopril (SQ 14,225) in a patient with primary pulmonary hypertension. Postgrad Med J. 1981 Feb;57(664):115–116. doi: 10.1136/pgmj.57.664.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Korr K. S., Gandsman E. J., Winkler M. L., Shulman R. S., Bough E. W. Hemodynamic correlates of right ventricular ejection fraction measured with gated radionuclide angiography. Am J Cardiol. 1982 Jan;49(1):71–77. doi: 10.1016/0002-9149(82)90279-x. [DOI] [PubMed] [Google Scholar]
  8. Krayenbuehl H. P., Turina J., Hess O. Left ventricular function in chronic pulmonary hypertension. Am J Cardiol. 1978 Jun;41(7):1150–1158. doi: 10.1016/0002-9149(78)90872-x. [DOI] [PubMed] [Google Scholar]
  9. Lloyd T. C., Jr Hypoxic pulmonary vasoconstriction: role of perivascular tissue. J Appl Physiol. 1968 Nov;25(5):560–565. doi: 10.1152/jappl.1968.25.5.560. [DOI] [PubMed] [Google Scholar]
  10. Maslowski A. H., Ikram H., Nicholls M. G., Espiner E. A. Haemodynamic, hormonal, and electrolyte responses to captopril in resistant heart failure. Lancet. 1981 Jan 10;1(8211):71–74. doi: 10.1016/s0140-6736(81)90004-0. [DOI] [PubMed] [Google Scholar]
  11. Niarchos A. P., Roberts A. J., Laragh J. H. Effects of the converting enzyme inhibitor (SQ 20881) on the pulmonary circulation in man. Am J Med. 1979 Nov;67(5):785–791. doi: 10.1016/0002-9343(79)90735-6. [DOI] [PubMed] [Google Scholar]
  12. Patterson J. A., Naughton J., Pietras R. J., Gunnar R. M. Treadmill exercise in assessment of the functional capacity of patients with cardiac disease. Am J Cardiol. 1972 Nov;30(7):757–762. doi: 10.1016/0002-9149(72)90151-8. [DOI] [PubMed] [Google Scholar]
  13. Prewitt R. L., Leffler C. W. Feline hypoxic pulmonary vasoconstriction is not blocked by the angiotensin I-converting enzyme inhibitor, captopril. J Cardiovasc Pharmacol. 1981 Mar-Apr;3(2):293–298. doi: 10.1097/00005344-198103000-00008. [DOI] [PubMed] [Google Scholar]
  14. RIVERA-ESTRADA C., SALTZMAN P. W., SINGER D., KATZ L. N. Action of hypoxia on the pulmonary vasculature. Circ Res. 1958 Jan;6(1):10–14. doi: 10.1161/01.res.6.1.10. [DOI] [PubMed] [Google Scholar]
  15. SEGEL N., HARRIS P., BISHOP J. M. The effects of synthetic hypertensin of the systemic and pulmonary circulations in man. Clin Sci. 1961 Feb;20:49–61. [PubMed] [Google Scholar]
  16. Stool E. W., Mullins C. B., Leshin S. J., Mitchell J. H. Dimensional changes of the left ventricle during acute pulmonary arterial hypertension in dogs. Am J Cardiol. 1974 Jun;33(7):868–875. doi: 10.1016/0002-9149(74)90634-1. [DOI] [PubMed] [Google Scholar]
  17. Zakheim R. M., Mattioli L., Molteni A., Mullis K. B., Bartley J. Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin I-converting enzyme in the rat. Lab Invest. 1975 Jul;33(1):57–61. [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES